Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 306

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection

Open access
Eskandary, Farsad, Regele, Heinz, Baumann, Lukas, Bond, Gregor, Kozakowski, Nicolas, Wahrmann, Markus, Hidalgo, Luis G., Haslacher, Helmuth, Kaltenecker, Christopher C., Aretin, Marie-Bernadette, Oberbauer, Rainer, Posch, Martin, Staudenherz, Anton, Handisurya, Ammon, Reeve, Jeff, Halloran, Philip F., Böhmig, Georg A.·2018·Journal of the American Society of Nephrology

Abstract

Export Late antibody-mediated rejection (ABMR) is a leading cause of kidney allograft failure. Uncontrolled studies have suggested efficacy of the proteasome inhibitor bortezomib, but no systematic trial has been undertaken to support its use in ABMR. In this randomized, placebo-controlled trial (the Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection [BORTEJECT] Trial), we investigated whether two cycles of bortezomib (each cycle: 1.3 mg/m2 intravenously on days 1, 4, 8, and 11) prevent GFR decline by halting the progression of late donor-specific antibody (DSA)–positive ABMR. Forty-four DSA-positive kidney transplant recipients with characteristic ABMR morphology (median time after transplant, 5.0 years; pretransplant DSA documented in 19 recipients), who were identified on cross-sectional screening of 741 patients, were randomly assigned to receive bortezomib (n=21) or placebo (n=23). The 0.5-ml/min per 1.73 m2 per year (95% confidence interval, −4.8 to 5.8) difference detected between bortezomib and placebo in eGFR slope (primary end point) was not significant (P=0.86). We detected no significant differences between bortezomib- and placebo-treated groups in median measured GFR at 24 months (33 versus 42 ml/min per 1.73 m2; P=0.31), 2-year graft survival (81% versus 96%; P=0.12), urinary protein concentration, DSA levels, or morphologic or molecular rejection phenotypes in 24-month follow-up biopsy specimens. Bortezomib, however, associated with gastrointestinal and hematologic toxicity. In conclusion, our trial failed to show that bortezomib prevents GFR loss, improves histologic or molecular disease features, or reduces DSA, despite significant toxicity. Our results reinforce the need for systematic trials to dissect the efficiency and safety of new treatments for late ABMR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1681/asn.2017070818

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Cited by

See all 306

Metadata

Authors
Eskandary, F., Regele, H., Baumann, L., Bond, G., Kozakowski, N., Wahrmann, M., Hidalgo, L. G., Haslacher, H., Kaltenecker, C. C., Aretin, M.-B., Oberbauer, R., Posch, M., Staudenherz, A., Handisurya, A., Reeve, J., Halloran, P. F., & Böhmig, G. A.
Venue
Journal of the American Society of Nephrology
Published
2017-12-14
Volume
29
Issue
2
Pages
591-605
ISSN
  • 1046-6673 (ISSN-L)
  • 1533-3450
OpenAlex
W2773812249
Cited by
306
References
33
FWCI
25.24
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection. https://app.cochat.ai/papers/10.1681/asn.2017070818
The paper
Eskandary, F., Regele, H., Baumann, L., Bond, G., Kozakowski, N., Wahrmann, M., Hidalgo, L. G., Haslacher, H., Kaltenecker, C. C., Aretin, M.-B., Oberbauer, R., Posch, M., Staudenherz, A., Handisurya, A., Reeve, J., Halloran, P. F., & Böhmig, G. A. (2018). A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2017070818

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.